Contact
searchSearch
HMP Global

Advertisement

Advertisement

ADVERTISEMENT

Hemophilia B Topic Center

Featured

News
Fitusiran Prophylaxis Shows Promise for Protection Against Bleeding for Patients With Hemophilia A or B
06/05/2024
Grace Taylor, MS, MA
A phase 3 study evaluated the efficacy and safety of fitusiran in males with hemophilia A or B who were receiving bypassing agent (BPA)/clotting factor concentrate (CFC) prophylaxis.
A phase 3 study evaluated the efficacy and safety of fitusiran in males with hemophilia A or B who were receiving bypassing agent (BPA)/clotting factor concentrate (CFC) prophylaxis.
A phase 3 study evaluated the...
06/05/2024
First Report Managed Care
News
Study Finds No Treatment-Related Adverse Events in Boys Treated With Purified FIX Concentrate
05/09/2024
Jolynn Tumolo
Purified factor IX (FIX) concentrate was effective in treating and preventing bleeding episodes in real-world pediatric patients 6 years and younger with hemophilia B, according to a study published in the Journal of Blood Medicine.
Purified factor IX (FIX) concentrate was effective in treating and preventing bleeding episodes in real-world pediatric patients 6 years and younger with hemophilia B, according to a study published in the Journal of Blood Medicine.
Purified factor IX (FIX)...
05/09/2024
First Report Managed Care
News
Rebalancing Coagulation Pathways and Human Factor 9 Gene Knock-In Strategy Identified for Hemophilia B
04/25/2024

Grace Taylor

Grace Taylor
A study published in Molecular Therapy Nucleic Acids highlights a treatment strategy for treating hemophilia B by combining rebalancing coagulation pathways and human factor 9 (hF9) gene knock-in (KI) using a lipid nanoparticle and...
A study published in Molecular Therapy Nucleic Acids highlights a treatment strategy for treating hemophilia B by combining rebalancing coagulation pathways and human factor 9 (hF9) gene knock-in (KI) using a lipid nanoparticle and...
A study published in Molecular...
04/25/2024
First Report Managed Care
News
Antibody Test Determines Eligibility for Hemophilia Gene Therapy
12/11/2023
Jolynn Tumolo
The US Food and Drug Administration’s recent approval of the AAV5 DetectCDx test marked the agency’s first-ever approval of a companion diagnostic test for a gene therapy product.
The US Food and Drug Administration’s recent approval of the AAV5 DetectCDx test marked the agency’s first-ever approval of a companion diagnostic test for a gene therapy product.
The US Food and Drug...
12/11/2023
First Report Managed Care
News
Patient Education on AAV Vectors for Hemophilia Essential to Prevent ‘Buyer’s Remorse’
11/10/2023
Jolynn Tumolo
Having long served as the model disorders for the development of gene therapy, hemophilia A (HA) and hemophilia B (HB) are currently benefitting from the role with the emergence of adeno-associated viral (AAV) vectors, according to a review...
Having long served as the model disorders for the development of gene therapy, hemophilia A (HA) and hemophilia B (HB) are currently benefitting from the role with the emergence of adeno-associated viral (AAV) vectors, according to a review...
Having long served as the model...
11/10/2023
First Report Managed Care
News
Changing Trends in Hemophilia Treatment
10/27/2023
Julie Gould
“With other novel therapies (including gene therapy) entering the US market, it is important to document the variability in existing prescribing practices among broad-based cohorts of clinicians,” explain study authors.
“With other novel therapies (including gene therapy) entering the US market, it is important to document the variability in existing prescribing practices among broad-based cohorts of clinicians,” explain study authors.
“With other novel therapies...
10/27/2023
First Report Managed Care
News
Gene Therapy Superior to Factor IX Replacement for Hemophilia B
04/17/2023
Jolynn Tumolo
Findings from a phase 3 trial suggest gene therapy was superior to prophylactic factor IX for decreasing bleeding in patients with hemophilia B.
Findings from a phase 3 trial suggest gene therapy was superior to prophylactic factor IX for decreasing bleeding in patients with hemophilia B.
Findings from a phase 3 trial...
04/17/2023
First Report Managed Care
News
For Most Patients, Factor Replacement Likely Unnecessary Up to 25 Years After Gene Therapy for Hemophilia B
03/02/2023
Jolynn Tumolo
Predictive analyses suggest a majority of patients with hemophilia B likely would achieve durable clotting factor levels after a single infusion of etranacogene dezaparvovec.
Predictive analyses suggest a majority of patients with hemophilia B likely would achieve durable clotting factor levels after a single infusion of etranacogene dezaparvovec.
Predictive analyses suggest a...
03/02/2023
First Report Managed Care
Ajeet Gajra, MD, FACS
Videos
Survey Assesses Community Oncologists/Hematologists’ Perceptions of Gene Therapy for Hematological Disorders
01/21/2022
Ajeet Gajra, MD, FACS, discusses survey results analyzing community oncologists/hematologists’ perceptions of gene therapies and barriers to adoption or integration into clinical practice.
Ajeet Gajra, MD, FACS, discusses survey results analyzing community oncologists/hematologists’ perceptions of gene therapies and barriers to adoption or integration into clinical practice.
Ajeet Gajra, MD, FACS, discusses...
01/21/2022
Journal of Clinical Pathways
From Journal of Clinical Pathways
First Report
Decreased Medication, Utilization Costs Identified With Emicizumab-kxwh Therapy for Hemophilia
08/31/2020

Edan Stanley

Edan Stanley
Emicizumab-kxwh, which was approved by the FDA in November 2017 to prevent or reduce the frequency of bleeding episodes in patients with hemophilia (HEM) A and FVIII inhibitors, was found to be associated with decreased medication and...
Emicizumab-kxwh, which was approved by the FDA in November 2017 to prevent or reduce the frequency of bleeding episodes in patients with hemophilia (HEM) A and FVIII inhibitors, was found to be associated with decreased medication and...
Emicizumab-kxwh, which was...
08/31/2020
First Report Managed Care
Formulary Frontlines®
Innovations in Managing Hemophilia
08/26/2019

Eileen Koutnik-Fotopoulos

Eileen Koutnik-Fotopoulos
Although hemophilia is designated an orphan disease by the FDA because it affects fewer than 200,000 people in the United States, it imposes a significant financial and burden on patients, caregivers, and society.
Although hemophilia is designated an orphan disease by the FDA because it affects fewer than 200,000 people in the United States, it imposes a significant financial and burden on patients, caregivers, and society.
Although hemophilia is...
08/26/2019
First Report Managed Care

Newsfeed

News
Fitusiran Prophylaxis Shows Promise for Protection Against Bleeding for Patients With Hemophilia A or B
06/05/2024
Grace Taylor, MS, MA
A phase 3 study evaluated the efficacy and safety of fitusiran in males with hemophilia A or B who were receiving bypassing agent (BPA)/clotting factor concentrate (CFC) prophylaxis.
A phase 3 study evaluated the efficacy and safety of fitusiran in males with hemophilia A or B who were receiving bypassing agent (BPA)/clotting factor concentrate (CFC) prophylaxis.
A phase 3 study evaluated the...
06/05/2024
First Report Managed Care
News
Study Finds No Treatment-Related Adverse Events in Boys Treated With Purified FIX Concentrate
05/09/2024
Jolynn Tumolo
Purified factor IX (FIX) concentrate was effective in treating and preventing bleeding episodes in real-world pediatric patients 6 years and younger with hemophilia B, according to a study published in the Journal of Blood Medicine.
Purified factor IX (FIX) concentrate was effective in treating and preventing bleeding episodes in real-world pediatric patients 6 years and younger with hemophilia B, according to a study published in the Journal of Blood Medicine.
Purified factor IX (FIX)...
05/09/2024
First Report Managed Care
News
Rebalancing Coagulation Pathways and Human Factor 9 Gene Knock-In Strategy Identified for Hemophilia B
04/25/2024

Grace Taylor

Grace Taylor
A study published in Molecular Therapy Nucleic Acids highlights a treatment strategy for treating hemophilia B by combining rebalancing coagulation pathways and human factor 9 (hF9) gene knock-in (KI) using a lipid nanoparticle and...
A study published in Molecular Therapy Nucleic Acids highlights a treatment strategy for treating hemophilia B by combining rebalancing coagulation pathways and human factor 9 (hF9) gene knock-in (KI) using a lipid nanoparticle and...
A study published in Molecular...
04/25/2024
First Report Managed Care
News
Antibody Test Determines Eligibility for Hemophilia Gene Therapy
12/11/2023
Jolynn Tumolo
The US Food and Drug Administration’s recent approval of the AAV5 DetectCDx test marked the agency’s first-ever approval of a companion diagnostic test for a gene therapy product.
The US Food and Drug Administration’s recent approval of the AAV5 DetectCDx test marked the agency’s first-ever approval of a companion diagnostic test for a gene therapy product.
The US Food and Drug...
12/11/2023
First Report Managed Care
News
Patient Education on AAV Vectors for Hemophilia Essential to Prevent ‘Buyer’s Remorse’
11/10/2023
Jolynn Tumolo
Having long served as the model disorders for the development of gene therapy, hemophilia A (HA) and hemophilia B (HB) are currently benefitting from the role with the emergence of adeno-associated viral (AAV) vectors, according to a review...
Having long served as the model disorders for the development of gene therapy, hemophilia A (HA) and hemophilia B (HB) are currently benefitting from the role with the emergence of adeno-associated viral (AAV) vectors, according to a review...
Having long served as the model...
11/10/2023
First Report Managed Care
News
Changing Trends in Hemophilia Treatment
10/27/2023
Julie Gould
“With other novel therapies (including gene therapy) entering the US market, it is important to document the variability in existing prescribing practices among broad-based cohorts of clinicians,” explain study authors.
“With other novel therapies (including gene therapy) entering the US market, it is important to document the variability in existing prescribing practices among broad-based cohorts of clinicians,” explain study authors.
“With other novel therapies...
10/27/2023
First Report Managed Care
News
Gene Therapy Superior to Factor IX Replacement for Hemophilia B
04/17/2023
Jolynn Tumolo
Findings from a phase 3 trial suggest gene therapy was superior to prophylactic factor IX for decreasing bleeding in patients with hemophilia B.
Findings from a phase 3 trial suggest gene therapy was superior to prophylactic factor IX for decreasing bleeding in patients with hemophilia B.
Findings from a phase 3 trial...
04/17/2023
First Report Managed Care
News
For Most Patients, Factor Replacement Likely Unnecessary Up to 25 Years After Gene Therapy for Hemophilia B
03/02/2023
Jolynn Tumolo
Predictive analyses suggest a majority of patients with hemophilia B likely would achieve durable clotting factor levels after a single infusion of etranacogene dezaparvovec.
Predictive analyses suggest a majority of patients with hemophilia B likely would achieve durable clotting factor levels after a single infusion of etranacogene dezaparvovec.
Predictive analyses suggest a...
03/02/2023
First Report Managed Care
News
ICER Report Finds Hemophilia Biosimilar Cost-Effective
01/29/2018
A recent cost-effectiveness report from ICER examined the value of Hemlibra (emicizumab-kxwh; Genentech), a biosimilar that treats hemophilia A.
A recent cost-effectiveness report from ICER examined the value of Hemlibra (emicizumab-kxwh; Genentech), a biosimilar that treats hemophilia A.
A recent cost-effectiveness...
01/29/2018
First Report Managed Care
News
FDA Approves Long-Acting Hemophilia B Treatment
03/07/2016
The FDA approved Idelvion (coagulation factor IX [recombinant], albumin fusion protein; CSL Behring) for use in children and adults with hemophilia B. This is the first coagulation factor-albumin fusion protein product and the second factor...
The FDA approved Idelvion (coagulation factor IX [recombinant], albumin fusion protein; CSL Behring) for use in children and adults with hemophilia B. This is the first coagulation factor-albumin fusion protein product and the second factor...
The FDA approved Idelvion...
03/07/2016
First Report Managed Care
News
AHA Voices Concern Over CMS Payment Updates to LTC Hospitals
08/07/2024
The American Hospital Association (AHA) expressed deep concern in response to long-term care (LTC) hospital payment updates finalized by the Centers for Medicare & Medicaid (CMS) on August 1, 2024.
The American Hospital Association (AHA) expressed deep concern in response to long-term care (LTC) hospital payment updates finalized by the Centers for Medicare & Medicaid (CMS) on August 1, 2024.
The American Hospital...
08/07/2024
First Report Managed Care
News
Obesity Linked to Distinct Heart Muscle Abnormalities in Patients With HFpEF, Study Finds
08/05/2024
A recent study published in Nature Cardiovascular Research highlighted the significant impact of severe obesity on myocardial ultrastructure in patients with heart failure with preserved ejection fraction (HFpEF), revealing potential...
A recent study published in Nature Cardiovascular Research highlighted the significant impact of severe obesity on myocardial ultrastructure in patients with heart failure with preserved ejection fraction (HFpEF), revealing potential...
A recent study published in...
08/05/2024
First Report Managed Care
News
New Treatment Options Benefit Patients With Relapsed/Refractory Follicular Lymphoma
08/05/2024
Patients with relapsed/refractory follicular lymphoma tend to have a poorer response and shortened progression-free survival with each subsequent treatment, but new treatment options are emerging.
Patients with relapsed/refractory follicular lymphoma tend to have a poorer response and shortened progression-free survival with each subsequent treatment, but new treatment options are emerging.
Patients with...
08/05/2024
First Report Managed Care
Conference Coverage
Centering Patients Within Value-Based Care
07/30/2024
Asembia 2024 speakers Olivia Banyon and Sean McCabe discuss the concept of value-based care, patient-centered care, clinician well-being, and system workflows to improve the quality of life for patients.
Asembia 2024 speakers Olivia Banyon and Sean McCabe discuss the concept of value-based care, patient-centered care, clinician well-being, and system workflows to improve the quality of life for patients.
Asembia 2024 speakers Olivia...
07/30/2024
First Report Managed Care
News
Sun Exposure Linked With Lower Risk of Follicular Lymphoma
07/30/2024
High sun exposure in warmer months may protect against the development of follicular lymphoma, according to a study published in the journal Cancer Epidemiology, Biomarkers & Prevention.
High sun exposure in warmer months may protect against the development of follicular lymphoma, according to a study published in the journal Cancer Epidemiology, Biomarkers & Prevention.
High sun exposure in warmer...
07/30/2024
First Report Managed Care
News
Updated CDC Recommendation for RSV Vaccination in Older Adults
07/29/2024
The Center for Disease Control and Prevention (CDC) vaccine advisory group updated its recommendation for the use of the respiratory syncytial virus (RSV) vaccine in older adults so that people ages 60 to 74 with certain underlying conditions...
The Center for Disease Control and Prevention (CDC) vaccine advisory group updated its recommendation for the use of the respiratory syncytial virus (RSV) vaccine in older adults so that people ages 60 to 74 with certain underlying conditions...
The Center for Disease Control...
07/29/2024
First Report Managed Care
Bill McElnea
Conference Coverage
Unlocking the Value-Based Care Potential of Health System Specialty Pharmacies
07/26/2024
Asembia 2024 speaker Bill McElnea discusses the role of health system specialty pharmacies in reducing total cost of care, enhancing medication adherence, and improving outcomes under value-based care arrangements.
Asembia 2024 speaker Bill McElnea discusses the role of health system specialty pharmacies in reducing total cost of care, enhancing medication adherence, and improving outcomes under value-based care arrangements.
Asembia 2024 speaker Bill...
07/26/2024
First Report Managed Care
News
Meta-Analysis Shows Bidirectional Link Between Psoriasis and Asthma
07/26/2024
A recent systematic review and meta-analysis spanning 12.4 million patients found a significant bidirectional association between psoriasis and asthma. Researchers published their findings online in BMC Pulmonary Medicine.
A recent systematic review and meta-analysis spanning 12.4 million patients found a significant bidirectional association between psoriasis and asthma. Researchers published their findings online in BMC Pulmonary Medicine.
A recent systematic review and...
07/26/2024
First Report Managed Care
News
HIV Cases Rise Among Gay Latinos
07/24/2024
As HIV rates continue to rise among Latino gay and bisexual men, health policy advocates stress the need for more federal assistance for HIV treatment and prevention in this community.
As HIV rates continue to rise among Latino gay and bisexual men, health policy advocates stress the need for more federal assistance for HIV treatment and prevention in this community.
As HIV rates continue to rise...
07/24/2024
First Report Managed Care
Quiz
COPD and RSV Infection Incidences
07/23/2024
True or False: Patients with chronic obstructive pulmonary disease (COPD) have a lower incidence of RSV infection compared to the general population because treatments for COPD also alleviate the symptoms of RSV.
True or False: Patients with chronic obstructive pulmonary disease (COPD) have a lower incidence of RSV infection compared to the general population because treatments for COPD also alleviate the symptoms of RSV.
True or False: Patients with...
07/23/2024
First Report Managed Care

Advertisement

Advertisement

FRMC Volume 21, Issue 2

Current Issue

June 2024
Volume 21
Issue 2
Current Issue
Issue Archive

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Privacy Policy Terms of Use

Advertisement

Advertisement